Targeted Delivery of Losartan Using a Biodegradable Polymeric Nanocarrier for the Management of Hypertension-Associated Vascular Remodeling

Background: Hypertension manifests through endothelial dysfunction, oxidative stress, and vascular remodeling. Angiotensin II–AT1 receptor signaling contributes to these processes, supporting the role of angiotensin-receptor blockade in vascular disease management. Losartan is an established AT1 receptor blocker, while biodegradable polymeric nanocarriers may allow for extended drug release and altered pharmacokinetics. [1,3,4] Objective: The present study aims to characterize antihypertensive treatment patterns and record vascular or cardiovascular findings among 120 patients with hypertension who received care in selected tertiary-care hospitals in Punjab, Pakistan. This observational study will also establish the framework for subsequent evaluation of a losartan-loaded biodegradable polymeric nanocarrier. Methods: The observational part of this study will involve retrospective extraction of demographical, blood-pressure, comorbidity, laboratory, prescription, treatment modification, adherence, and vascular or cardiovascular imaging data. A prospective experimental program will also be designed, which will entail formulation and characterization of a biodegradable losartan nanocarrier, followed by in-vitro release trials, pharmacokinetic assessment, and safety and efficacy studies prior to clinical investigations. Results: Please note that the results section cannot be generated without the actual data extracted from the 120 patient records. For this reason, the present manuscript provides the framework for observational analyses without presenting hypothetical findings. Similarly, the proposed biodegradable nanocarrier for losartan delivery is a concept that requires extensive preclinical and clinical investigations before safety and efficacy can be established. Conclusion: Hospital records represent a valuable source of real-world evidence regarding treatment patterns and clinical outcomes associated with specific therapeutic approaches. The present study will generate practice-level insights and support the design of a future nanomedicine program for hypertension. Specifically, a biodegradable polymeric nanocarrier for losartan delivery will require extensive physicochemical, toxicological, pharmacokinetic, preclinical, and clinical evaluations before it can be considered a viable therapeutic option.